The Function of SUMOylation and Its Critical Roles in Cardiovascular Diseases and Potential Clinical Implications

Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent bonds on the backbones or amino acid side chains of proteins and expand the diversity of proteins, which provides the basis for the emergence of organismal complexity. To date, more than 650 types of protein modifications, such as the most well‐known phosphorylation, ubiquitination, glycosylation, methylation, SUMOylation, short‐chain and long‐chain acylation modifications, redox modifications, and irreversible modifications, have been described, and the inventory is still increasing. By changing the protein conformation, localization, activity, stability, charges, and interactions with other biomolecules, PTMs ultimately alter the phenotypes and biological processes of cells. The homeostasis of protein modifications is important to human health. Abnormal PTMs may cause changes in protein properties and loss of protein functions, which are closely related to the occurrence and development of various diseases. In this review, we systematically introduce the characteristics, regulatory mechanisms, and functions of various PTMs in health and diseases. In addition, the therapeutic prospects in various diseases by targeting PTMs and associated regulatory enzymes are also summarized. This work will deepen the understanding of protein modifications in health and diseases and promote the discovery of diagnostic and prognostic markers and drug targets for diseases.

show abstract

“…UBC9 adds a SUMO group to GATA4 at K366, which activates particular gene expression in pluripotent cardiac cells. 1051 …”

Section: Sumoylationmentioning

confidence: 99%

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Zhong

Xiao

Xie

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Wang et al reported that SUMO1 deficiency can cause cardiac septal dysplasia and congenital heart disease [ 32 ]. SUMOylation of GATA4, GATA5, and GATA6 regulates cardiac value and expression [ 33 ]. SUMOylation of GATA4 activates the modification of SUMO-1 at K445 and regulates the expression of cardiac protein in cardiogenic genes [ 34 ].…”

Section: Ptms In Heart Developmentmentioning

confidence: 99%

Role of Posttranslational Modifications of Proteins in Cardiovascular Disease

Liu

Zhang

Wen

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has become a leading cause of mortality and morbidity globally, making it an urgent concern. Although some studies have been performed on CVD, its molecular mechanism remains largely unknown for all types of CVD. However, recent in vivo and in vitro studies have successfully identified the important roles of posttranslational modifications (PTMs) in various diseases, including CVD. Protein modification, also known as PTMs, refers to the chemical modification of specific amino acid residues after protein biosynthesis, which is a key process that can influence the activity or expression level of proteins. Studies on PTMs have contributed directly to improving the therapeutic strategies for CVD. In this review, we examined recent progress on PTMs and highlighted their importance in both physiological and pathological conditions of the cardiovascular system. Overall, the findings of this review contribute to the understanding of PTMs and their potential roles in the treatment of CVD.

show abstract

“…Interestingly, SUMO1 knockout mice are survivable because SUMO2/3 can compensate for most functions of SUMO1 (Zhang et al, 2008;Wang et al, 2014a). SUMO1 and SUMO2/3 are common, while SUMO4 is only expressed in few organs, such as spleen and kidney (Du et al, 2021). SUMO4 is associated with the pathogenesis of type I diabetes mellitus.…”

Section: Sumo Proteinsmentioning

confidence: 99%

Natural Products Against Renal Fibrosis via Modulation of SUMOylation

et al. 2022

View full text Add to dashboard Cite

Renal fibrosis is the common and final pathological process of kidney diseases. As a dynamic and reversible post-translational modification, SUMOylation and deSUMOylation of transcriptional factors and key mediators significantly affect the development of renal fibrosis. Recent advances suggest that SUMOylation functions as the promising intervening target against renal fibrosis, and natural products prevent renal fibrosis via modulating SUMOylation. Here, we introduce the mechanism of SUMOylation in renal fibrosis and therapeutic effects of natural products. This process starts by summarizing the key mediators and enzymes during SUMOylation and deSUMOylation and its regulation role in transcriptional factors and key mediators in renal fibrosis, then linking the mechanism findings of SUMOylation and natural products to develop novel therapeutic candidates for treating renal fibrosis, and concludes by commenting on promising therapeutic targets and candidate natural products in renal fibrosis via modulating SUMOylation, which highlights modulating SUMOylation as a promising strategy for natural products against renal fibrosis.

show abstract

The Function of SUMOylation and Its Critical Roles in Cardiovascular Diseases and Potential Clinical Implications

Cited by 16 publications

References 150 publications

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Role of Posttranslational Modifications of Proteins in Cardiovascular Disease

Natural Products Against Renal Fibrosis via Modulation of SUMOylation

Contact Info

Product

Resources

About